KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Revenue (2016 - 2025)

Historic Revenue for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to $611.1 million.

  • Sarepta Therapeutics' Revenue rose 6837.66% to $611.1 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1577.99%. This contributed to the annual value of $1.9 billion for FY2024, which is 5297.39% up from last year.
  • Sarepta Therapeutics' Revenue amounted to $611.1 million in Q2 2025, which was up 6837.66% from $112.0 million recorded in Q1 2025.
  • Sarepta Therapeutics' 5-year Revenue high stood at $658.4 million for Q4 2024, and its period low was $112.0 million during Q1 2025.
  • For the 5-year period, Sarepta Therapeutics' Revenue averaged around $305.7 million, with its median value being $256.0 million (2022).
  • Data for Sarepta Therapeutics' Revenue shows a peak YoY increase of 6837.66% (in 2025) and a maximum YoY decrease of 7291.18% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Revenue stood at $201.5 million in 2021, then rose by 28.28% to $258.4 million in 2022, then skyrocketed by 53.54% to $396.8 million in 2023, then soared by 65.94% to $658.4 million in 2024, then decreased by 7.19% to $611.1 million in 2025.
  • Its Revenue was $611.1 million in Q2 2025, compared to $112.0 million in Q1 2025 and $658.4 million in Q4 2024.